Potential role of nonstatin cholesterol lowering agents

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• Statins, inhibitors of 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR), effectively lower low-density lipoproteins but cause side effects in some patients.
• The cause of statin side effects is debated, possibly linked to intrinsic toxicity or reduced essential isoprenoid end products.
• Cholesterol synthesis involves multiple enzymes beyond HMGR, presenting opportunities for alternative therapeutic strategies.

Purpose of the Study:

• To explore non-statin approaches for hypercholesterolemia management by targeting enzymes downstream of HMGR.
• To review the structure-function relationships of squalene synthase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase (OSC).
• To highlight the potential advantages of inhibiting these downstream enzymes compared to traditional statin therapy.

Main Methods:

• Literature review focusing on the structure-function relationships of FDFT1, SQLE, and OSC.
• Analysis of the cholesterol synthesis pathway to identify key downstream targets.
• Comparison of potential therapeutic benefits between HMGR inhibition and downstream enzyme inhibition.

Main Results:

• Inhibiting FDFT1, SQLE, and OSC could lower plasma cholesterol levels.
• This downstream inhibition may preserve ubiquinone, dolichol, and other vital isoprenoid metabolisms.
• FDFT1, SQLE, and OSC are identified as promising, though understudied, targets for novel hypercholesterolemia drugs.

Conclusions:

• Targeting enzymes downstream of HMGR represents a promising 'non-statin' strategy for hypercholesterolemia.
• Inhibition of FDFT1, SQLE, and OSC offers a potential alternative to statins with a possibly improved side effect profile.
• Further research into FDFT1, SQLE, and OSC is warranted for developing new lipid-lowering therapies.